Table 8.
Risk groups to clinically significant cancers stratified by the FPd molecular scores
| High | Intermediate | Low | |
| Risk score1 | |||
| n (%) | 13 (33) | 14 (36) | 12 (31) |
| Median (min–max) | (0.6064–1.0000) | (0.1735–0.5297) | (0.0489–0.1706) |
| Gleason score ≥7 | |||
| n (%)2 | 12 (92) | 4 (29) | 1 (8) |
| RR (H vs. L), P3 | 10.150 (1.556–66.260), P < 0.0001 | ||
| RR (H vs. [I + L]), P4 | 4.800 (2.149–10.720), P < 0.0001 | ||
| High risk of recurrence by NCCN5 | |||
| n (%)2 | 8 (62) | 1 (7) | 0 (0) |
| RR (H vs. L), P | Undefined, P = 0.0016 | ||
| RR (H vs. [I + L]), P | 16.000 (2.232–114.700), P = 0.0002 | ||
| No. of cores ≥3 | |||
| n (%)2 | 11 (85) | 8 (57) | 5 (42) |
| RR (H vs. L), P | 2.031 (1.000–4.125), P = 0.0414 | ||
| RR (H vs. [I + L]), P | 1.692 (1.080–2.651), P = 0.0449 | ||
| Max.% cancer inv. in any core ≥50% | |||
| n (%)2 | 9 (69) | 5 (36) | 0 (0) |
| RR (H vs. L), P | Undefined, P = 0.0005 | ||
| RR (H vs. [I + L]), P | 3.600 (1.512–8.570), P = 0.0041 | ||
| Insignificant cancer by the Epstein criteria6 | |||
| n (%)2 | 0 (0) | 0 (0) | 6 (50) |
| RR (L vs. H), P | Undefined, P = 0.0052 | ||
| RR (L vs. [H + I]), P | Undefined, P = 0.0003 | ||
NCCN, National Comprehensive Cancer Network; PSAD, prostate-specific antigen density; RR, relative risk.
FPd molecular score: FPd = −3.481 + 0.803*log 2 Fx(III, IV, ETS) + 10.854*PSAD, High-grade cancer risk score = 1/(1 + e(−FPd)).
% Of each risk group or positive predictive value in 39 biopsy positive patients.
RR between high- and low-risk group with 95% CI, P value of Fisher exact test.
RR between high- and intermediate + low-risk group with 95% CI, P value of Fisher exact test.
Gleason score ≥8, PSA ≥ 20 ng/mL or T3a as defined by the NCCN guidelines.
Gleason score ≤6, no. of cores ≤2, percentage cancer involvement ≤50%, and PSAD ≤ 0.15 ng/mL met at the same time. RR between low- and high-, low- and high + intermediate (H + I)-risk group with 95% CI, P value of Fisher exact test.